Abacavir + Lamivudine + ZidovudineThird Party Manufacturing in India

This triple NRTI combination works by comprehensively inhibiting the HIV-1 reverse transcriptase enzyme through premature DNA chain termination.

All three molecules—Abacavir, Lamivudine, and Zidovudine—must be intracellularly phosphorylated to their active triphosphate forms. These active metabolites compete with endogenous nucleotides, integrating into the elongating viral DNA strand and stopping further viral DNA synthesis.

Unlike dual therapies, this triple-nucleoside regimen provides robust suppression of viral replication with a single class of drugs, often simplifying treatment by avoiding drug interactions associated with other antiretroviral classes. It is highly effective and well-tolerated for patients requiring alternative antiretroviral regimens.

Therapeutic Uses

This triple NRTI combination is prescribed for the treatment of:

• HIV-1 Infection: Used as a complete antiretroviral regimen or as part of a broader combination therapy.
• Viral Load Management: Effectively suppresses HIV replication, lowering the viral load to undetectable levels.
• Treatment Simplification: Offers a convenient, single-tablet regimen that avoids complex drug-drug interactions often seen with protease inhibitors or NNRTIs.

Why Manufacturers Choose This Combination

Triple NRTI combinations are critical tools in the global fight against HIV, particularly in settings where alternative regimens are contraindicated or unavailable. The formulation of three active pharmaceutical ingredients into a single, stable dosage form requires specialized manufacturing expertise.

This makes the Abacavir, Lamivudine, and Zidovudine combination a highly sought-after product for third party manufacturing in India, with consistent demand from export markets, NGOs, and global tender supplies.